MedTrace Logo

Effect of Antioxidant Docosahexaenoic Acid (DHA) in Cystic Fibrosis Patients

NCT04987567 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2021-08-03

No results posted yet for this study

Summary

This study evaluates the effect of antioxidant docosahexaenoic acid (DHA) in patients with cystic fibrosis. Half of participants will receive DHA, while the other half will receive placebo.

Conditions

  • Cystic Fibrosis in Children

Interventions

DIETARY_SUPPLEMENT

ANTIOXIDANT DHA TRIGLYCERIDE (TRIDOCOSAHEXAENOINE-AOX®)

Pearls of DHA (BrudyNen)

DIETARY_SUPPLEMENT

PLACEBO (OLIVE OIL)

Pearls manufactured to mimic DHA (BrudyNen).

Sponsors & Collaborators

  • Corporacion Parc Tauli

    lead OTHER

Principal Investigators

  • Roser Ayats Vidal, MD · Parc Tauli Hospital from Sabadell (Barcelona). Spain.

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-21
Primary Completion
2020-02-20
Completion
2020-02-20

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04987567 on ClinicalTrials.gov